Sleep in Psychiatric Care (SIP): A Transdiagnostic Group-based Sleep-school as Treatment for Comorbid Delayed Sleep-Wake Phase Disorder (DSWPD)
Phase: NA
Conditions: Delayed Sleep-Wake Phase Disorder, Sleep Disorder, Psychiatric Disorder
Sponsor: Haukeland University Hospital

1 of 12 
02.06.2020 12:53 
Project description for the Research Project:  
Non-pharmacological sleep-treatment in groups for people with 
psychiatric illness: Sleep in Psychiatric Care (SIP) 
NCT-numbers: NCT04463498 and NCT05177055  
Version date: 09.06.2023 
1. Excellence 
1.1. State of the art, knowledge needs and project objectives 
Sleep has been underrated for decades in medicine [1] despite the fact that improved sleep reduces  
psychiatric symptoms [2] and poor sleep is longitudinally linked to impaired somatic health [3]. In 2017, the 
Nobel Prize for Medicine or Physiology was awarded to scientists who showed that humans have a network 
comprising of timekeeping genes that are repeated in a daily cycle. These timekeeping genes are associated 
with timing of sleep and wakefulness as well as mental disorders such as depression, bipolar disorders, and 
other mood disorders. This important acknowledgment of sleep and circadian rhythms` relation to mental 
health, has turned the wheel towards increased focus on sleep-related scientific knowledge [1]. The main 
idea behind this project is to bring a focus on sleep into psychiatric care (SIP) and to provide an evidence-
based approach of delivering non-pharmacological sleep-treatment to people with psychiatric illness.  
The projects in this proposal are based on several important theoretical findings. First, disrupted 
and poor sleep are associated with the development, relapse, or worsening of mental disorders and also 
increased suicidal ideation [4]. Polysomnography studies on sleep and mental disorders show that 
problems with maintenance of sleep are observed in most mental disorders while sleep architecture 
alterations compared to normal sleep are observed in all mental disorders except for ADHD and seasonal 
affective disorder [5]. Sleep and mental health have a bidirectional relationship, but there is a knowledge 
gap on whether interventions to improve sleep also improve mental health in patients with moderate to 
severe psychiatric illness [2]. About 50% of patients visiting their general practitioner fulfil the criteria for 
chronic insomnia [6] and 45-70% of patients with depression, bipolar disorder, anxiety disorder, and PTSD 
have been shown to have significant sleep disruption [7, 8]. Cognitive behavioural therapy for insomnia 
(CBTi) is the recommended treatment option for chronic insomnia disorder worldwide, but its effect on 
patients with comorbid moderate to severe psychiatric illness is mainly documented in single-disorder 
randomized controlled studies (RCTs) [6]. A recent feasibility study from Sweden showed that CBTi 
delivered in groups is a clinically feasible treatment option for insomnia in an outpatient setting among 
patients diagnosed with depression, bipolar disorder, anxiety disorders, and PTSD [7]. In a recent series on 
sleep and sleep disorders in the Lancet, the authors point out that very few high-quality intervention 
studies exist and that treatment for circadian rhythm disorders are hindered by a scarcity of tools for 
measuring sleep and circadian physiology [9]. Chronotherapy (e.g., sleep hygiene, timed light exposure, and 
the use of chronobiotic medications), shows promising effects within psychiatric treatment [9]. Also, a high 
prevalence of personality disorders has been found decades ago in circadian rhythm sleep disorders, 
though the focus on this comorbidity seem to have gotten increased attention in later years [10]. 
Transdiagnostic interventions, which are based on the assumption that many differential disorders share 
common etiological and maintenance process [11], targeting sleep in psychiatric illness has received 
increased attention in the past decade [9, 12-14]. Also, disturbances of the circadian system have been 

2 of 12 
02.06.2020 12:53 
implicated in the development of several somatic illnesses such as cancer and cardiovascular diseases as 
well as in neuropsychiatric disorders [9]. Hence, sleep plays a pivotal role for health in the entire organism.  
In this project the objective is to investigate the effects of two non-pharmacological group-based 
treatments for patients with insomnia and the most common circadian rhythm sleep-wake disorder; 
delayed sleep-wake phase disorder (DSWPD), respectively, in which both sleep disorders are comorbid with 
moderate to severe mental illness. We will investigate the effect on subjective and objective sleep 
measures and on symptoms of psychiatric illness. By treating the sleep disorders adjacent to their mental 
illness, we will be able to fill the gaps of the abovementioned knowledge needs. We will examine the 
potential benefits of sleep-treatment on a wide array of symptoms and areas of human functioning, 
because sleep plays a role in all aspects of the human body.     
1.2. Novelty and ambition 
The current project is highly innovative and underlines the importance of cross-disciplinary - including user-
representative - collaboration. Findings from this study will improve our understanding of the 
development, relapse, and remission of moderate to severe mental disorders, the importance of sleep and 
the sleep-wake cycle including neurophysiology in health and illness and could change the way we design 
future package sequences in the mental health care sector. This could lead to new scientific discoveries and 
improved treatment interventions. The results have the potential to change the way we think about, teach 
new therapists (medical doctors, psychologists, psychiatric nurses, and other health personnel), and not the 
least the way we treat patients with mental illness and comorbid sleep disorders. This project is to our 
knowledge the first to combine state-of-the-art knowledge about chronotherapy with knowledge from the 
extensive research on the benefits of CBTi on sleep and psychiatric symptoms. It is also the first to examine 
the potential benefits of non-pharmacological sleep treatment in moderate to severely mentally ill patients 
on a wide array of functionalities.  
Particularly innovative aspects of this project:  
- 
We focus our attention on a patient group otherwise often excluded from research protocols, even 
though a vast amount of time and money is invested every day to treat this patient group.  
- 
We treat sleep disorders co-jointly with psychiatric disorders in a psychiatric setting.   
- 
The broad outcome measures and the combination of self-report and objective measures.   
- 
We will study a treatment already implemented as a treatment in a clinic, making it easier and 
more feasible to implement in other clinics. The project is hence based on clinical practice that 
already is experienced as effective and appreciated by therapists and patients. We now plan to test 
this clinically successful model with gold-standard evidence-based methodology.  
- 
The sleep-treatment in groups is a cost-effective way of delivering sleep-treatment and we do it in 
a slow open fashion where patients can be referred anytime. After the pre-consultation with a 
member of the sleep-team, a date of sleep-treatment initiation is given, regardless of waitlists. This 
is a flexible format and does not require a lot of resources in the clinic.   
- 
We will study the psychophysiology (such as blood pressure and heart-rate-variability; HRV) in 
patients with sleep- and psychiatric disorder. This may lead to new insights into the interconnection 
between sleep-wake regulation, psychophysiology, and psychiatric symptoms. 
- 
We will investigate whether personality traits become changed in 12 months in patients with sleep 
disorders and psychiatric illness after successful treatment, which has not been investigated before, 
only suggested by several researchers in the field. 
- 
We evaluate personality disorders (using a diagnostic manual, the SCID-5-PF) in all patients with 
DSWPD, which has been documented in the 1990`s to be prevalent in circadian rhythm sleep 
disorders. This has not been taken further scientifically for two-three decades. The knowledge we 

3 of 12 
02.06.2020 12:53 
will gain from this, will not only be important in the field of sleep and circadian rhythm sleep 
disorders, but also in the field of personality disorders.    
- 
We will study work attendance, welfare benefits, medication use, suicide attempts and 
admittances in psychiatric care before, during and after the non-pharmacological sleep-treatment.    
- 
We are conducting two RCTs in a more naturalistic setting than what is often the case since the 
intervention group and control group are in outpatient psychiatric treatment during the 
experimental period. This improves the generalizability to clinical settings, which often is a 
limitation in RCTs.    
- 
We build on the new and innovative research that indicates dark-therapy (in our project by using 
blue light blocking glasses (bb-glasses) as a promising treatment for mental illness and sleep 
disorders, for the first time investigating this as an additive treatment to more established 
treatment protocols in a group of patients with identified sleep disorders comorbid to moderate to 
severe mental illness. This along with non-pharmacological, psychological and behavioral 
treatment, represents a much desired alternative to the use of hypnotics to mend sleep problems. 
Although the treatment basis in this project is not new, this is the first study to use the research in 
treatment for insomnia and DSWPD without excluding moderate to severe mental illness. It is also the first 
RCT to our knowledge to study the effect of treatment for insomnia and DSWPD on such a wide array of 
functionalities as planned here, in a group setting, in a naturalistic context. We use state-of-the-art 
treatment and implement it in an outpatient psychiatric clinic. The treatment has so far mainly shown 
effect for patients with sleep disorders only or just mild to moderate specific mental illnesses such as 
depression, bipolar disorder, or ADHD. Our ambition is to investigate - and if the results do not contradict 
our hypotheses - later develop a model and manual for non-pharmacological sleep treatment in groups for 
people with psychiatric illness into a recommended standard, first-choice treatment for comorbid sleep 
disorders in moderate to severe mental illness. We plan to develop treatment manuals which ease the 
transferability to other psychiatric settings. The model is designed to fit the government-regulated package 
sequences all patients in psychiatric care are required to receive. We argue that the project also has an 
innovative side where established treatment is being used in a new manner, in a new setting and where it 
is possible to test the treatment digitally (or hybrid with face-to-face and digital follow-up) in later studies.  
 
1.3. Research questions and hypotheses, theoretical approach and methodology 
We will test the following hypotheses in two work-packages (WPs): 
1. An RCT with 60 psychiatric outpatients with comorbid insomnia and moderate to severe mental 
illness to investigate the positive impacts of an additive group-based treatment for insomnia 
compared to treatment as usual in psychiatric care while on a wait-list for non-pharmacological 
sleep-treatment in groups. 
2. An RCT with 60 outpatients with comorbid DSWPD and moderate to severe mental illness to 
investigate the positive impacts of an additive group-based treatment for DSWPD compared to 
treatment as usual in psychiatric care while on a wait-list for non-pharmacological sleep-treatment 
in groups. 
The specific aims of this project are to test the following hypotheses:  
WP 1 
Primary hypothesis: Group-based sleep intervention based on CBTi reduces insomnia symptoms and 
symptoms of anxiety and depression significantly more than treatment as usual while on a waitlist for non-
pharmacological sleep-treatment in groups (TAU + WL). 

4 of 12 
02.06.2020 12:53 
Primary outcome measures: Insomnia Severity Index (ISI), the Bergen Insomnia Scale (BIS), and Sleep Onset 
latency (SOL), Wake after sleep onset (WASO), and Sleep efficiency (SE) from sleep diaries, Becks 
Depression Inventory (BDI-II) and Becks Anxiety Inventory (BAI).   
Secondary hypothesis: Group-based sleep intervention based on CBTi reduces symptoms in a range of areas 
including fatigue, sleep, attention deficits, dysfunctional beliefs about sleep, and improves well-being, 
attention, and daytime function significantly more than treatment as usual while on a waitlist for non-
pharmacological sleep-treatment in groups (TAU + WL). 
The use of bb-glasses enhances the effect of the group-based treatment for insomnia on SOL. 
WP 2 
Primary hypothesis: Group-based sleep intervention with light therapy at gradually advanced timing 
advances sleep timing and reduces symptoms of anxiety and depression significantly more than treatment 
as usual while on a waitlist for non-pharmacological sleep-treatment in groups (TAU + WL). 
Primary outcome measures: Measured subjectively and objectively by sleep diaries, Genactiv actigraphy, 
and saliva samples (intraindividual variation of rise time (IIV), dim light melatonin onset (DLMO), rise /wake 
up-time), Becks Depression Inventory (BDI-II) and Becks Anxiety Inventory (BAI). 
Secondary hypothesis: Group-based sleep intervention with light therapy at gradually advanced timing 
reduce symptoms in a range of areas including fatigue, sleep, attention deficits, dysfunctional beliefs about 
sleep and improve well-being, attention, and daytime function significantly more than treatment as usual 
while on a waitlist for non-pharmacological sleep-treatment in groups (TAU + WL). 
The use of bb-glasses enhances the effect of the group-based treatment for DSWPD on SOL. 
Figure 1. Overview of the project and the two WPs. 
 
WL= Wait list. TAU=treatment as usual, bb-glasses=Blue-blocking glasses  
 
Two randomized controlled trials (RCTs) will be undertaken in order to obtain an evidence-based treatment 
model in psychiatric outpatient care for patients with moderate to severe mental illness and comorbid 
sleep disorders (insomnia and DSWPD).  
Choice of method: We have chosen to use the gold standard for experimental trials, RCT, as the 
methodological design for WP1 and 2. We want to conduct a naturalistic, yet controlled study that is 
generalizable to common clinical practice and outpatient psychiatric clinics. Hence, the participants will 
already be patients at an outpatient clinic and are not to be recruited from outside the clinic (such as from 
the general population). We use an RCT design to avoid confounding biases and in order to be as sure as we 
can that the intervention in the experimental condition represents the only difference between the groups 
we study. Most studies on sleep disorders exclude moderate to severe mental illness hence leaving the 
research results not generalizable to the patient group that may benefit from sleep interventions the most 
leaving a large knowledge gap regarding these patient groups. In this project, however, that is the specific 
Non-pharmacological sleep-treatment in groups for people with psychiatric illness
N= 120
WP1: Insomnia n=60
Sleep treatment in groups 
5 sessions over 
8 weeks n=30
Additive bb-
glasses
n=15
No additive 
treatment
n=15
WL + TAU
n=30
WP2: DSWPD n=60
Sleep treatment in groups 
4 sessions over 
6 weeks n=30
Additive bb-
glasses
n=15
No additive 
treatment
n=15
WL + TAU
n=30

5 of 12 
02.06.2020 12:53 
group we want to recruit and investigate, and we seek to close this gap concerning the effects of evidence-
based treatment studies for sleep disorders. Since we are investigating a tormented and vulnerable group 
of patients that traditionally have low daytime function and tend to receive welfare, we find it particularly 
important to have user representatives as part of the project group to speak for the patients.   
Inclusion and exclusion criteria for WP 1 and 2:  
Inclusion criteria:  
- 
Patients referred to, are offered, and who accepts attendance at the sleep-school at Bjørgvin DPS 
psychiatric hospital (BDPS) 
- 
Patients fulfilling the Diagnostic Manual for Mental Disorders (DSM-V) criteria for insomnia/DSWPD 
- 
Patients who have comorbid moderate to severe psychiatric illness operationalized as;  
1. Confirmed clinician-evaluated F-diagnosis based on the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10/11) diagnostic system that are used in Norway 
2. and/or scores of >19 on BDI and/or scores of >15 on BAI at the time of referral to the sleep 
school 
Exclusion Criteria: 
- 
Nightwork or shift work that overlaps with the patients` regular bedtime 
- 
Not able to fill out questionnaires online even with help from others (either because of language 
barriers, functionality barriers or ability level) 
Power analysis for the insomnia RCT 
Power analysis was conducted with G*Power, version 3.1.9.2 [15]. Relevant effect sizes (Hegdes g) for 
power analyses were based on a recent meta-analysis of randomized controlled trials aiming at improving 
sleep, but that also reported an impact on mental health. The meta-analysis reported (following the 
removal of outliers) a large pooled effect size (g = 0.97) on sleep quality. The pooled effect size for 
composite mental health outcomes was g = 0.42 [16]. Another relevant meta-analysis on the effects of CBTi 
in patients with mental disorders and comorbid insomnia showed that effect sizes (Hedges g) for reduction 
of insomnia severity post-treatment were 0.50 for patients with depression, 1.50 for patients with PTSD, 
1.40 for patients with alcohol dependency, 1.20 for patients with psychosis/bipolar disorder, and 0.80 for 
patients with mixed comorbidities, respectively. Effects on mental health symptom severity post-treatment 
were 0.50 for depression, 1.30 for PTSD, 0.90 for alcohol dependency (only one study), 0.30 for 
psychosis/bipolar, and 0.80 for mixed comorbidities [17]. Against this background an assumed effect size 
(Cohens d) for insomnia symptoms (primary outcome) of 0.80 was expected, whereas an expected effect 
size of 0.40 was deemed reasonable for the secondary (mental health) outcomes. Analyzing the data using 
ANOVA, setting the alpha to .05, power (1 – β) set to .80, and the correlation coefficient between repeated 
measures to r = .50, showed that 16 patients are needed to detect significant time (pre-post) x group 
(treatment vs. wait-list) interaction effects. In terms of the secondary outcomes (d= 0.40), a similar power 
analysis showed that a total of 52 patients are required. Taking into consideration an attrition rate of 10%, 
we aim, based on this power analysis, to recruit a total of 60 patients. For the sub-sample in the treatment 
group using additive bb-glasses, we base our power calculation on a study reporting ES of 1.6 [18]. 
Following the same procedure as above, we need 6 participants to show a significant time (pre-post) x 
group (standard care vs. treatment) interaction.   
Power analysis for the DSWPD RCT 
The power analysis for the delayed sleep-wake phase disorder (DSWPD) group was based on estimates of 
changes in dim light melatonin onset, which is one of the most important primary outcomes. Based on a 
previous controlled study [19] we calculated the effect size, using the Comprehensive Meta-Analysis, 
version 4.0, [20] in favor of the bright light intervention on this parameter to equal a Cohens d of 0.64 at 
posttreatment. Based on this we assumed an effect size (Cohens d) for DLMO (primary outcome) of 0.60. 
Setting the alpha to .05, power (1 – β) set to .80, and the correlation coefficient between repeated 
measures to r = .50, showed that 24 patients are needed to detect significant time (pre-post) x group 

6 of 12 
02.06.2020 12:53 
(treatment vs. wait-list) interaction effects. No previous study has investigated secondary (mental health) 
outcomes of light treatment for DSPRD. Hence, we assumed a similar effect size (d= .40) as for the 
secondary outcomes related to CBTi for insomnia. As shown above, recruiting 60 patients should then be 
sufficient, also when taking attrition into account. Taken together the power analyses showed that for 
detecting significant improvement on the primary outcome measures for insomnia and the DSWPD-group 
post-treatment 16, and 24 patients need to be recruited, respectively. However, in order to be able to 
detect improvement in the secondary outcomes and to take attrition into account as well we should recruit 
60 patients in total, in each of the two patent groups. No study has investigated the additive effect of bb-
glasses to light therapy at gradually advanced timing for DSWPD. 
Randomization procedures: Randomization was performed by: https://www.randomizer.org/ before 
inclusion. When a new patient is referred to the sleep team and meets the inclusion criteria evaluated in an 
individual pre-consultation before the group-based sleep-school, the patient is asked if they want to 
participate in the study. If they say yes, they are assigned either to Sleep-school or waitlist while in 
treatment as usual (TAU + WL) based on a pre-defined list. All receive a date the Sleep-school starts without 
being told whether or not they are assigned to a wait-list condition. They are also assigned a date for data 
collection at two time-points. For the Sleep-school group this is before (T1) and after (T2) Sleep-school, 
while for those in the TAU + WL condition are assigned T1 and T2 at least 8 (WP1) or 6 (WP2) weeks apart 
before they start the Sleep-school. Hence, blinding is not completely ensured, but not overt. Wait-list for 
specific treatments in psychiatric care is normal.  
Stability in the treatment in the Sleep-school: The content (slides, hand-outs, video material) and the plan 
for each session in the sleep-school remains the same throughout the project. The structure has been 
tested over 4 years before we started recruiting and hence it is well tested. AWL and VKV has lead these 
groups together as co-therapists since 2017 and plan to continue until 2026 and onwards. In case of sick-
leave or other unexpected circumstances, there are colleagues who can fill in for the sleep team. To ensure 
that the included patients receives the same treatment, we will not change the content or the structure of 
the sleep-school as long as we are collecting data for these projects. TAU will naturally vary with different 
therapists. This study is a naturalistic study in a clinic as it is, which will increase generalizability of our 
research.   
Risks: In terms of risks and risk-mitigation table 1 below presents an overview 
Table 1: Risk and risk-mitigation related to the project 
Risk 
Probability 
Severity 
Mitigating action 
Problems 
recruiting 
patients 
Low 
 
High 
If occurring, advertising to increase recruitment is possible and multi-cites may be 
established in Helse-Bergen. 
Equipment 
malfunction  
Medium 
Medium 
Continuously ensure data quality. Have stand-by replacement equipment  
Unequal gender 
balance 
Medium 
Medium 
Take this into account in the analyses and analyze for gender differences. 
 
Adverse events 
Medium 
High 
We can not rule out the possibility of suicide attempts or suicidal behavior 
occurring while participating in the study. If that happens, the clinic has 
procedures for such events and trained personnel available.   
Ethical considerations: The two work-packages will be carried out according to the Helsinki-declaration, the 
Vancouver-recommendations, Good clinical practice (GCP), and CONSORT-guidelines. The project is 
approved by the Regional Ethics Committee of Western Norway, REK West, project number: 66304, and 
both WP are registered in ClinicalTrials.gov. The projects are also registered at helsenorge.no. Patients that 
are referred to the sleep school that decline participation in the research project or that do not meet the 
inclusion criteria, will still receive the treatment if considered to fulfill criteria for participating in the Sleep-

7 of 12 
02.06.2020 12:53 
school otherwise. The wait-list group will start the active sleep school treatment immediately after the 6- or 
8 weeks of waiting (waitlist guarantee), while in treatment as usual for their psychiatric illness. 
Gender perspectives: We will aim at recruiting 50% men and 50% women to the studies and if we end up 
with unequal gender balance, we will take this into account in the analyses and analyze for gender 
differences. 
Stakeholder considerations: Sleep problems are common, but a widespread available treatment is not 
common. This project may provide a feasible solution to this lack of available non-pharmacological 
treatment and can be implemented on all levels in the health care.   
2. Impact 
The results can provide valuable knowledge on the association between sleep disorders and psychiatric 
illness and inform on the impact of an effective and time-efficient treatment for the most common 
comorbidity in psychiatric care. If the results show that group-based sleep-interventions can reduce both 
sleep problems and psychiatric symptoms to a larger extent than treatment as usual, we will recommend a 
change in clinical practice. Therapists are often overloaded with patient work and may then be relieved of 
treating patients with comorbid sleep and psychiatric illness - and focus on patients and treatments that 
require individual therapy. This can lead to shorter successful treatment for those where sleep is their main 
problem and can lead to cost-effectiveness in the health-economy. The structure of this group-based 
treatment is possible to implement in district psychiatric centers (DPS) nationally and can potentially 
improve public access to sleep treatment, which is highly beneficial since insomnia is a predictor of 
subsequent work disability [21]. This can also give GPs a highly welcomed non-pharmaceutical treatment 
option to refer patients to instead of giving them hypnotics or antidepressants for their sleep problems 
[22]. The results from this project can be the beginning of the important task of closing the knowledge gap 
between state-of-the-art science within the sleep area and the need for improved interventions and 
models in psychiatric clinics.  
2.1. Potential impact of the proposed research 
When the project is completed, we have a vast amount of new knowledge that can be used in optimizing 
treatment at BDPS and other DPS`s nationally and similar outpatient clinics internationally. If the results 
from this project show that a group-based sleep school over 6 / 8 weeks improves not only sleep measures 
but also psychiatric symptoms, reduce medication use and reduces the length of treatment, we will 
manualize the treatment and train therapists to become sleep school leaders based on the protocol and 
organization used in this project, hence manualizing this model. With the knowledge obtained from this 
project, it might be possible to tailor treatment and offer it to those who most likely will benefit from it. 
Hence, this project can potentially increase the effectiveness of the treatment in psychiatric health care.   
In the field of psychiatry, the results from this project might be of great importance because sleep 
disorders in many cases are an obstacle to other treatment (the client has DSWPD and sleeps from 8 am to 
16 pm, making attendance to therapy sessions difficult or a patient with comorbid insomnia cannot benefit 
from psychotherapy because of issues with fatigue and attention). One–on–one talk therapy can be very 
time-consuming and if this project shows significant improvement also in psychiatric symptoms, patients 
and therapists can be saved from many time-consuming treatments that otherwise may not be very 
successful. The treatment in this project may in some cases be all the patient needs, work as a pre-
treatment before other protocols (i.e. trauma-treatment) and in some cases be adjacent to individual 
therapy, enhancing its effects. 
2.1 Potential for societal impact of the research project (optional) 

8 of 12 
02.06.2020 12:53 
This project has the potential to address the UN sustainable goal number 3: Good health and well-being. 
Sleep problems are common and can be treated relatively quickly, hence SIP has the potential to target 
good health and well-being wherever the treatment is implemented.  
 
2.2. Measures for communication and exploitation 
Communication with other stakeholders: Summaries of results and interpretations with interest for a 
wider audience will be disseminated in appropriate outlets (e.g., the web pages at the University of Bergen 
and Helse-Bergen). In addition, the findings will be communicated to user groups, policymakers, and 
practitioners within medical and mental health services through lectures and the media, as well as the 
general public. The project group has a long experience in cooperation with national media channels and 
public outreach that will allow us to implement an effective communication and dissemination plan for this 
project. Throughout the project, preliminary results will be presented at national and international research 
conferences.  
Scientific results: Results will be published in internationally acknowledged peer-reviewed open-access 
journals within medicine, psychiatry, and psychology. We expect to publish at least 8 international 
publications based on the findings from the current project within the project period. Working titles for the 
articles are:  
1. Comorbid insomnia and moderate to severe psychiatric illness: A treatment protocol for a 
naturalistic, randomized controlled trial (manuscript is almost ready as first draft) 
2. Comorbid delayed sleep-wake phase disorder and moderate to severe psychiatric illness: A 
treatment protocol for a naturalistic, randomized controlled trial 
3. Group-based cognitive behavioural therapy for insomnia in a transdiagnostic sample at a 
psychiatric outpatient clinic: A randomized controlled trial 
4. Group-based chronotherapy for delayed sleep-wake phase disorder in a transdiagnostic sample 
at a psychiatric outpatient clinic: A randomized controlled trial  
5. Personality disorders and Delayed sleep-wake phase disorder in a transdiagnostic psychiatric 
sample 
6. Psychophysiological changes after treatment for insomnia in a transdiagnostic psychiatric 
sample 
7. Executive functions and attention deficits in patients with sleep disorders comorbid to 
psychiatric illness 
8. Changes in work attendance after treatment for sleep disorders comorbid to psychiatric illness 
3. Implementation 
3.1 Researcher and project group 
Project manager: Ane Wilhelmsen-Langeland (AWL), specialist in clinical psychology, PhD and certified 
somnologist at BDPS, a general psychiatric outpatient clinic. Leader of the sleep team at BDPS. Member 
of the research group Bergen Sleep- and Chrononobiology network (BeSCN) at the University of Bergen 
(UoB). Has lead the sleep school at BDPS clinically since the spring of 2017 together with psychiatric 
nurse VAV. AWL will lead the clinical part of the group based sleep school and manage the data 
collection, scoring and plotting, analysis and interpretation of data, write articles based on the results 
and disseminate the results in relevant academic fields as well as to the general public. She has 
experience doing all of this. We apply for free purchase of her time 50% from other clinical duties in 
order to be able to handle the data load and write the articles from SIP in close collaboration with the 
project group members. 

9 of 12 
02.06.2020 12:53 
Berge Osnes (BO) is a specialist in clinical psychology, PhD, and holds a position as associate professor 
at the Department of Clinical Psychology, UoB. He is a member of the research group Emotion and 
Cognition Group (ECG). BO has taken part in the design and planning of this project and will take part in 
data collection and his main expertise in this project is in HRV, neuropsychology and neurophysiology. 
He is also an experienced clinician. He will participate in analyzing and interpreting the data. 
Psychiatric registered nurse Veronika Alice Vågenes (VAV) is part of the sleep team at BDPS and 
facilitates the sleep school groups together with AWL. She will take part in leading the sleep school 
groups (in which she already has been for 6 years), and be a research fellow in SIP. She will collect data, 
organize and execute several tasks in SIP. We apply for 20% research fellow position for her to relief her 
of some clinical tasks. She also starts her Masters` degree this year in Collaboration and Public Health at 
the Western University of Applied Sciences and she will write her Masters` thesis based on SIP.   
Professor Ståle Pallesen (SP). Department of Psychosocial Science and Norwegian Competence Center 
for Sleep Disorders member of BeSCN, somnologist, has led and supervised large sleep related projects. 
SP has taken part in the planning and design of the study.  
Professor Bjørn Bjorvatn (BB) works at the Department of global public health and primary care, UoB, 
is the leader of the Norwegian Competence center for Sleep Disorders (SOVno), and the leader Center 
for Sleep medicine at HUS. He is a member of BeSCN, he is a somnologist and has led many large sleep 
related research projects. BB has taken part in the planning and design of the study. 
Ingvild West Saxvig (IWS) works as a senior advisor at the Norwegian Competence Center for Sleep 
Disorders (SOVno), is a somnologist and Registered Polysomnography technician (RPSGT), member of 
BeSCN, PhD. IWS has taken part in the planning and design of the study. 
Professor Lin Sørensen (LS) at Institute for biological and medical psychology, UoB, has her specific 
expertise in neuropsychology, she is the leader of the research group ECG. LS will take part in 
interpreting the data related to her areas of expertise. 
Professor emeritus Ole Bernt Fasmer (OBF) works at the Clinical Institute 1, UoB. His expertise in this 
project is among others within mathematical analyses of timeseries, motoractivity and heart rate. OBF 
will take part in interpreting the data related to his areas of expertise.  
User representatives: Ove Vestheim who works in division of psychiatry as an advisor/peer supporter 
has been involved in SIP since the start. Arild Sørensen from the patient organization “Søvnforeningen” 
will onwards be invited to all meetings in the project group. They will both visit in the groups and give 
us feedback throughout. They are also available for the participants in SIP. Hjernerådet will be invited 
to the yearly seminaries and mid-evaluation meetings with the project group.   
International project group members:   
Professor Michael Gradisar (MG) works in Sleep Cycle which is a company promoting sleep using 
technology and has been a Professor at Flinders University in Adelaide, Australia. He was part of the 
task force in the National Sleep Foundation Poll (USA, 2011). He has made important scientific 
contributions to the field of adolescent sleep and DSWPD. MG will advise in interpreting the data 
related to DSWPD. 
Julian König (JK) is deputy Head of Research, University Hospital of Child and Adolescent Psychiatry and 
Psychotherapy, University of Bern, and Head of lab, Section for Experimental Child and Adolescent 
Psychiatry, Department of Child and Adolescent Psychiatry, University of Heidelberg. JK is a renowned 
capacity on HRV, and will take part in interpreting the data related to his areas of expertise and in the 
drafting of scientific articles. All project group members will take part in writing the scientific articles. 
 
3.2 Project organisation and management 

10 of 12 
02.06.2020 12:53 
Work plan and tasks: Recruitment, data collection, scoring, plotting and analysis of data, writing, critically 
reviewing, submitting articles, and disseminating results will take place between the last quarter of 2021 
and the last quarter of 2026 (see details in Gantt chart below). Dissemination will likely extend further than 
2026. Patients are referred to the sleep school at BDPS where AWL and VKV are on-site. Data-collection is 
done continuously as patients are recruited to participate in the study. Because of the slow-open group-
treatment, this is possible to follow up continuously. Five patients have already been to their 12-month 
follow up data collection. AWL and VKV assign full days every two-three months to score and plot data, 
hence some data have already been plotted. We will continue doing this throughout the study period when 
feasable.  
Preliminary data: As of January 2023 we did preliminary analysis where we tested Cohens` d on the first 9 
participants in WP1. We found large effect sizes (ES) of 1.9 for insomnia symptoms (ISI), 1.34 for sleep 
efficiency (SE) and medium (0.53, 0.79 and 0.72) for total sleep time, depression and anxiety in the Sleep-
school group, while in the TAU + WL group the ES were negative (-0.28) for total sleep time, and low to 
medium (0.57, 0.12, 0.22 and 0.29) respectively for the same variables. 
Gantt chart:  
 
Probability of recruiting enough patients within the time frame: As of June 9th 2023 we have recruited 23 
patients to WP 1 (recruitment started December 15th 2021) and 14 patients to WP2 (recruitment started 
June 20th 2022). With the current pace of recruitment, we will have recruited 60 patients for WP1 by the 
end of 2025 and 60 patients for WP2 by the third quarter of 2026. Referrals to the sleep-school has 
increased by over 30% in 2023 compared to corresponding timeline in 2022. We have not made any 
attempt to increase recruitment to the studies, we only recruit from patients being referred as part of 
clinical practice. It is possible to do more to recruit referrals if we find it necessary later on. We will do an 
evaluation of this by the end of 2024.  
 
Resources:  
3. Project manager AWL will lead both WPs; 2024-2026 in a 100% position. BDPS funds this as of now 
but free purchase from clinical duties besides the Sleep team is warranted in order to complete the 
projects as planned.   
4. Research assistant VAV will work 20% on this project with WP1 and 2 over 3 years; 2024-2026. She 
will keep her clinical position at BDPS. Her Master thesis will be based on SIP.  
5. BO can use some of his assistant professor position at UoB for data collection, analysis of data, 
writing, critically reviewing, submitting articles, and disseminating results. 
Q1
Q2
Q3
Q4 Q1 Q2
Q3
Q4
Q1 Q2
Q3
Q4
Work-package 1
Recruitment
15.12.21
31.10.25
AWL, VAV
Data collection
15.12.21
31.12.25
AWL, VAV, BO
Scoring, plotting, analyze data
14.02.21
30.04.26
AWL, VAV, BO
KD
Write, critically review and submit articles
01.01.23
31.12.26
All project group members
Disseminate results
01.10.26
31.12.26
AWL, BO
Work-package 2
Recruitment
20.06.22
30.06.26
AWL, VAV
Data collection
20.06.22
30.06.26
AWL, VAV, BO
Scoring, plotting, analyze data
20.08.22
30.06.26
AWL, VAV, BO
KD
Write, critically review and submit articles
03.03.24
31.12.26
All project group members
Disseminate results
01.10.26
31.12.26
AWL, BO
Milestones
Seminary for the project group
12.01.24
All project group members
Seminary mid-evaluation
11.01.25
All project group members
Seminary for the project group
10.01.26
All project group members
WP1 data collection completed for RCT
31.12.25
AWL, VAV, BO
WP2 data collection completed for RCT
30.06.26
AWL, VAV, BO
Key Deliveries (KD): data listings for statistical 
analysis finalized
Table 1. Gantt shows the project management for SIP
START 
DATE
Task performed by project 
group member(s)
END 
DATE
TASK NAME
2025
2026
2024

11 of 12 
02.06.2020 12:53 
6. The rest of the project group will be consulted and will take part in the project as described as part 
of their existing jobs with no funding from this proposal.  
7. We aim to supervise psychology students who are writing their master thesis on topics related to 
these projects and that will provide more resources when it comes to scoring and plotting the data, 
as well as literature searches, and in some cases possibly also in the writing the scientific articles. 
Several project members hold positions at the UoB, hence access to students is ensured.    
 
Budget: AWL received 100.000 NOK in 2020 from The Norwegian Competence Center for Sleep Disorders 
for research within the sleep field which was used to buy equipment necessary to start recruitment. SP, BB 
and BDPS has paid for Actiheart devices (to measure HRV). Data collection in itself is implementable in the 
current positions and organization of the WPs. However, due to the large data load, we need funding for 
free purchase for the project leader (50%) and a research assistant (20%) from their clinical positions in 
order to be able to manage the data during the recruitment period and write the scientific reports/articles. 
Free purchase from clinical work accounts for 2.389.000 million NOK over the 3 years. Funding for the 
analyses of the saliva samples (261.000 NOK), for open-access publication fees (240.000 NOK), for paid user 
representatives (18.600 NOK), for meeting costs (41.400 NOK) and conferences (50.000 NOK) to stay up to 
date and for networking, is also required in order to follow through as planned with SIP. In total we apply 
for 3 million NOK.  
 
References 
1. 
The, L., Waking up to the importance of sleep. The Lancet, 2022. 400(10357): p. 973. 
2. 
Scott, A.J., et al., Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. 
Sleep Med Rev, 2021. 60: p. 101556. 
3. 
Tamar, S., C.-Z. Mairav, and T. Orna, Functional consequences of inadequate sleep in adolescents: A systematic review. 
Sleep Medicine Reviews, 2014. 18(1): p. 75-87. 
4. 
Liu, X., Sleep and adolescent suicidal behavior. Sleep, 2004. 27(7): p. 1351-8. 
5. 
Baglioni, C., et al., Sleep and mental disorders: A meta-analysis of polysomnographic research. Psychol Bull, 2016. 142(9): 
p. 969-990. 
6. 
Perlis, M.L., et al., Insomnia. The Lancet, 2022. 400(10357): p. 1047-1060. 
7. 
Cassel, M., et al., Clinical feasibility of cognitive behavioural therapy for insomnia in a real-world mixed sample at a 
specialized psychiatric outpatient clinic. BMC Psychiatry, 2022. 22(1): p. 600. 
8. 
Soehner, A.M. and A.G. Harvey, Prevalence and functional consequences of severe insomnia symptoms in mood and 
anxiety disorders: results from a nationally representative sample. Sleep, 2012. 35(10): p. 1367-75. 
9. 
Meyer, N., et al., Circadian rhythms and disorders of the timing of sleep. The Lancet, 2022. 400(10357): p. 1061-1078. 
10. 
McGowan, N.M. and K.E.A. Saunders, The Emerging Circadian Phenotype of Borderline Personality Disorder: Mechanisms, 
Opportunities and Future Directions. Curr Psychiatry Rep, 2021. 23(5): p. 30. 
11. 
Fusar-Poli, P., et al., Transdiagnostic psychiatry: a systematic review. World Psychiatry, 2019. 18(2): p. 192-207. 
12. 
Harvey, A.G., A transdiagnostic approach to treating sleep disturbance in psychiatric disorders. Cogn Behav Ther, 2009. 38 
Suppl 1: p. 35-42. 
13. 
Harvey, A.G., New Frontiers in Empirically Grounded Treatment Generation for Insomnia, Depression, and Bipolar 
Disorder: Translational Research With Transdiagnostic Implications. International Journal of Cognitive Therapy, 2016. 
9(2): p. 171-180. 
14. 
Sheaves, B., et al., Adapted CBT to Stabilize Sleep on Psychiatric Wards: a Transdiagnostic Treatment Approach. 
Behavioural and Cognitive Psychotherapy, 2018. 46(6): p. 661-675. 
15. 
Faul, F., et al., G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. 
Behavior Research Methods, 2007. 39: p. 175-191. 
16. 
Scott, A.J., et al., Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials. 
Sleep Medicine Reviews, 2021. 60: p. article no. 101556. 
17. 
Hertenstein, E., et al., Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: 
A systematic review and meta-analysis. Sleep Medicine Reviews, 2022. 62: p. article no. 101597. 
18. 
Janků, K., et al., Block the light and sleep well: Evening blue light filtration as a part of cognitive behavioral therapy for 
insomnia. Chronobiology International, 2020. 37(2): p. 248-259. 
19. 
Geerdink, M., et al., Short blue light pulses (30 Min) in the morning support a sleep-advancing protocol in a home setting. 
Journal of Biological Rhythms, 2016. 31(5): p. 483-497. 
20. 
Biostat Inc., Comprehensive Meta‐Analysis, version 4.0 2022, Englewood, NJ: Biostat Inc. 
21. 
Sivertsen, B., et al., Insomnia and long sleep duration are risk factors for later work disability. The Hordaland Health Study. 
J Sleep Res, 2009. 18(1): p. 122-8. 

12 of 12 
02.06.2020 12:53 
22. 
Sivertsen, B., et al., Sleep problems in general practice: a national survey of assessment and treatment routines of general 
practitioners in Norway. J Sleep Res, 2010. 19: p. 36-41.